Biodegradable PLA Particles for Feed Conversion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccine formulations struggle to induce a balanced Th1 or Th2 immune response effectively, which is crucial for combating specific pathogens and diseases, as existing methods often require high antigen doses and lack efficient delivery mechanisms for inducing innate or adaptive immunity.
Innovation Solution
Development of biodegradable particulate vaccine formulations with specific diameters that are phagocytosed by antigen-presenting cells, incorporating polymeric or non-polymeric materials, adjuvants, and apoptosis inhibitors, administered in low antigen doses to induce a Th1 immune response, enhancing immune stimulation and weight gain in subjects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high antigen doses are used in current vaccine formulations, then immune response induction is attempted, but feed conversion rate deteriorates and weight gain is reduced
Solution Approach 1:
The patent changes the physical parameters of the antigen delivery system by using biodegradable particles with specific size ranges (0.1-10 μm) and controlled release characteristics. This allows effective immune response induction at lower antigen doses, improving feed conversion rate while maintaining immunogenicity.
Solution Approach 2:
The patent introduces biodegradable particles as intermediary carriers that mediate antigen delivery to antigen-presenting cells. These particles enhance antigen uptake and presentation efficiency, allowing lower antigen doses to achieve the same immune response, thereby improving productivity.
2Reliability
If high antigen doses are used in current vaccine formulations, then immune response induction is attempted, but weight gain deteriorates
Solution Approach 1:
The patent modifies the delivery system parameters using biodegradable particles with optimized size and release characteristics, enabling effective immune response at lower antigen doses, thus preserving weight gain while maintaining immunogenicity.
3Reliability
If biodegradable particles with small diameter are used to enable phagocytosis, then immune response efficiency is improved, but manufacturing precision requirements increase
Solution Approach 1:
The patent establishes specific particle diameter ranges (0.1-10 μm) that balance phagocytosis efficiency with manufacturing feasibility. This parameter optimization ensures particles are small enough for efficient cellular uptake while remaining producible with conventional manufacturing precision.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The biodegradable particle formulations effectively induce a Th1 immune response, improving survival rates, feed conversion, and weight gain in animals by stimulating innate or adaptive immunity with lower antigen doses, demonstrating potential in treating infections and enhancing immune responses.
Implementation Method 1
the disclosed biodegradable particles are phagocytosed by antigen presenting cells, such as macrophage and dendritic cells
Data Source
AI summary
Disclosed are compositions, kits, and methods for improving feed conversion rate in an animal in need thereof. The methods typically comprise administering orally to the animal a composition comprising biodegradable particles, the biodegradable particles comprising a polymer or a co-polymer comprising polylactide (PLA) and having an effective average diameter of 0.5-5 μm. In the methods, the animal is administered a dose of the biodegradable particles that is effective for improving feed conversion rate in the animal in comparison to an animal that is not administered the composition.